Homozygous mutations in
CBL have been found in a wide variety of myeloid neoplasms other than JMML.
CBL mutations are frequent in chronic myelomonocytic leukemia (5–13% of patients)
[41][42][43,44] and acute myeloid leukemia (AML), particularly forms secondary to myelodysplastic syndromes (9% of cases), suggesting that
CBL mutations may contribute to leukemia development
[9][41][9,43]. Furthermore,
CBL mutations could also be found in myelodysplastic syndromes, chronic myelogenous leukemia and other chronic myeloproliferative diseases
[9][41][42][9,43,44]. Similar to what has been described in JMML, the majority of patients show missense mutations clustering within the linker region and the RF domain
[9]. Less frequently, exon 8 deletions have been reported
[9][43][9,45]. Interestingly, most missense mutations are homozygous, while exon 8 deletions are usually heterozygous
[9]. Although in vitro studies demonstrated that expression of
CBL exon 8 and/or exon 9 deletions in a
CBL wild-type context shows a transforming phenotype, in the AML patients this alteration was found only in concomitance with other aberrations, particularly CBF leukemia
[44][46]. It is therefore possible to speculate that
CBL mutations may cooperate in the pathogenesis of this form of AML
[43][44][45,46]. Moreover, the majority of
CBL mutations in myeloid neoplasms have been reported in the absence of RAS or PTPN11 mutations, highlighting the mutual exclusivity of
CBL mutations and other RAS pathway alterations
[9]. The prognostic impact of
CBL mutations in myeloid malignancies is still controversial
[9][42][45][46][9,44,47,48]. To date, no clear clinical association has been established, and this should be a focus of research in future. Despite somatic mutations in
CBL being found in approximately 5% of myeloid neoplasms
[9], leukemia other than JMML have not been reported frequently in patients with germline
CBL mutations. To date, only two reports exist in the literature of AML developing in patients with
CBL syndrome. Becker et al. described a case of AML in an adult patient with a heterozygous de novo germline mutation in
CBL codon D390 located in the RF domain
[47][49]. Somatic leukemia cells presented with homozygous
CBL mutations resulting from copy-neutral LOH and an additional chromosomal gain at 11q. Additional mutations were found in the AML bone marrow, including inv(16) (p13q22)
[47][49]. Interestingly, the bone marrow maintained
CBL LOH even during complete remission and with normal blood counts, similar to what has been described in JMML
[28][36][37][28,36,37]. In another report, Ali et al. addressed the case of an adult patient with missense
CBL germline familial mutation in exon 8 developing AML. Leukemia arose due to copy-neutral LOH occurring through uniparental disomy. After induction chemotherapy, morphological remission was achieved, but atypical monocytosis and homozygous
CBL mutation persisted in the absence of the previously detected AML-associated mutations and chromosomal alterations. After the consolidation course, the bone marrow still presented the same reported morphological and genetic features. The clinicians therefore suspected an underlying chronic myelomonocytic leukemia or pre-neoplastic monocytic expansion, and performed haploidentical allo-HSCT from her non-CBL-carrying son, achieving complete chimerism and complete remission
[48][50]. A homozygous somatic mutation in
CBL (p.C381R) associated with an 11q-acquired uniparental disomy was found in one patient with T-ALL but without evidence of germline predisposition
[49][51].
4.3. CBL in Other Malignancies
The role of CBL in oncogenesis seems to not be limited to hematological malignancies. Somatic
CBL mutations have been reported in lung cancers
[50][51][54,55] while diffuse teratomas and embryonal rhabdomyosarcoma have been observed in patients with germline CBL mutations resulting in LOH in the CBL locus
[52][53][56,57]. Daniels et al. recently catalogued the mutational spectrum found in various tumors of the three genes:
CBL,
CBL-b, and
CBL-c in the TCGA database
[54][58]. The mechanism by which CBL contributes to the pathogenesis of solid tumors has not been completely clear. Other than the already discussed effect on the RAS pathway, a fascinating hypothesis is to consider the role of CBL in tumor-mediated angiogenesis
[55][59]. Tumors of c-
CBL knockout mice indeed exhibit increased growth and higher angiogenesis compared with wild-type mice
[56][60] (
Figure 3).
Figure 3. Known clinical manifestations of CBL mutations. The non-malignant phenotypes are an expression of germline CBL mutations. Cancers described in patients harboring a germline CBL mutation are highlighted in red. ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CML: chronic myelomonocytic leukemia; CNS: central nervous system; JMML: juvenile myelomonocytic leukemia; MDS: myelodisplastic syndrome.